argenx creates and develops highly differentiated antibodies for the treatment of severe autoimmune diseases and cancer. We are building and advancing our proprietary product portfolio. We are also providing our expertise through strategic antibody discovery and development partnerships.
With our proprietary portfolio, argenx focuses on novel disease targets and designs first-in-class or best-in-class products with distinct safety and efficacy profiles. We aim to advance our proprietary antibody products to clinical proof of efficacy in niche indications, after which we will partner them with industry leaders to rapidly bring treatments to the patients who need them.
argenx has one severe autoimmune asset in clinical phase and one in preclinical phase, Efgartigimod and ARGX-117. Proof-of-concept data were generated from 2 Phase 2 clinical trials in gMG and ITP. Efgartigimod is currently tested in one Phase 3 clincial trial in myasthenia gravis (MG) and two Phase 2 clinical trials in immune thrombocytopenia (ITP) and pemphigus vulgaris (PV). Efgartigimod will also be tested in chronic inflammatory demyelinating polyneuropathy (CIDP). ARGX-117 is still in preclinical development. Our oncology asset, ARGX-110, is currently tested in a Phase 2 clinical trial in cutaneous T-cell lymphoma (CTCL) and in a Phase 1/2 clinical trial in acute myeloid leukemia (AML). Our other oncology asset ARGX-111 is available for partnering. Our product pipeline also contains several discovery and preclinical stage programs, including a novel cancer immunotherapy program (ARGX-115) which has been partnered with AbbVie.
Through our strategic partnerships, argenx seeks to collaborate with leading pharma companies to combine their leadership in specific disease areas with our own cutting-edge antibody creation technologies and expertise.